Fluence Collaboration With Dutch Propagator WPK Creates Immediate Improvements in Plant Quality and Uniformity
14.9.2022 15:30:00 EEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its collaboration with Westlandse Plantenkwekerij (WPK), a large Dutch propagator specializing in young plant cultivation for greenhouse horticulture in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220914005286/en/
One of the larger propagators in the Netherlands, Westlandse Plantenkwekerij, implemented a hybrid lighting approach using Fluence’s VYPR fixtures, resulting in increased quality and control over environmental factors. (Photo: Business Wire)
Originally founded in the 1930s by Arie van der Arend, WPK is a multi-generational family business now run by van der Arend’s descendants, Erik and Eviek. As a propagator, WPK oversees the seed-to-plant process for vegetable and tray plants for growers throughout Europe. The company’s scientific approach to cultivation has led to decades of success, ultimately driving WPK to enlist Fluence’s help to install research-backed LED lighting at their ’s-Gravenzande facility, jointly owned with Plantenkwekerij P. van Geest, for the very first time.
WPK introduced Fluence’s VYPR Series top lights alongside existing legacy high-pressure sodium (HPS) fixtures to harness the unique control a hybrid lighting approach offers for optimizing environmental factors—including controlling ambient heat. The hybrid lighting model at WPK’s facilities has led to better management of seasonal growing conditions and notable energy savings.
“After installing Fluence’s LED lighting solutions, we learned that young plants thrive in LED-lit environments,” said Erik van der Arend, managing director of WPK. “This has allowed us the flexibility to grow a wide range of crops in the same environment and under the same lighting conditions, decreasing hassle and improving our energy costs. The transition to Fluence has helped improve plant quality and speed of development, ensuring our customers get a uniform product that is consistently excellent.”
In collaboration with Fluence’s horticultural lighting experts, WPK fine-tuned the LEDs’ spectra to optimize operational costs while maintaining superior quality for the grower’s tomato, cucumber, pepper and flower crops. Early results show that WPK is realizing an estimated electricity savings between 40 and 50% by using two-thirds Fluence LED fixtures and one-third HPS in the greenhouse. Additionally, WPK increased total light levels by 30% due to the overall efficiency of LED technology. The post-installation harvests produced more compact, generative and vigorous plants that were darker or richer in color.
“The interesting thing about Fluence’s lighting technology is the right degree of cooling—the luminaire doesn’t get very hot,” van der Arend added. “Moreover, the spectrum is widely applicable.”
“When you work with Fluence, you’re not just buying a standalone LED light. You’re tapping into a network of leading lighting and horticultural experts who can help you create the right conditions to optimize your cultivation environment,” said Timo Bongartz, general manager of Europe, Middle East and Africa at Fluence. “That’s why we love working with propagators like WPK who share our passion for developing innovative lighting and environmental control strategies.”
For more information about the collaboration, visit here.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About WPK
Westlandse Plantenkwekerij (WPK) is a specialist in vegetable cultivation for professional greenhouse horticulture in Europe. WPK was established in the 1930s and currently has four cultivation facilities: two in 's-Gravenzande (South-Holland) and two in Made (North-Brabant). WPK makes the world a little greener with the cultivation of vegetable plants (such as tomato, pepper and cucumber), tray plants and potted flowering plants.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005286/en/
Contact information
Media Contact:
For EMEA,
Silvia Nagyova
silvia.nagyova@fluence-led.com
+49 (89) 6213-3939
For North America,
Emma Chase
pr@fluencebioengineering.com
512-917-4319
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
